ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,212,105 | -65.8% | 337,052 | -60.6% | 0.00% | -66.7% |
| Q1 2023 | $9,402,074 | -21.9% | 854,734 | +5.1% | 0.00% | -25.0% |
| Q4 2022 | $12,042,000 | -3.7% | 813,622 | +24.3% | 0.00% | -20.0% |
| Q3 2022 | $12,510,000 | +7.9% | 654,678 | +20.3% | 0.01% | +25.0% |
| Q2 2022 | $11,596,000 | +40.0% | 544,188 | +26.5% | 0.00% | +100.0% |
| Q1 2022 | $8,285,000 | +84.6% | 430,262 | +98.8% | 0.00% | +100.0% |
| Q4 2021 | $4,489,000 | -48.1% | 216,403 | -40.2% | 0.00% | -66.7% |
| Q3 2021 | $8,655,000 | -10.6% | 362,035 | +2.0% | 0.00% | 0.0% |
| Q2 2021 | $9,686,000 | +5.6% | 354,880 | +11.9% | 0.00% | 0.0% |
| Q1 2021 | $9,176,000 | +183.4% | 317,203 | +175.5% | 0.00% | +200.0% |
| Q4 2020 | $3,238,000 | -61.1% | 115,117 | -59.5% | 0.00% | -66.7% |
| Q3 2020 | $8,334,000 | -0.9% | 284,446 | +2.3% | 0.00% | -25.0% |
| Q2 2020 | $8,407,000 | +10.9% | 278,019 | +9.3% | 0.00% | 0.0% |
| Q1 2020 | $7,584,000 | – | 254,439 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |